<DOC>
	<DOCNO>NCT01640093</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( body medication ) relative bioavailability 3 newly develop abiraterone acetate tablet formulation compare current commercial abiraterone acetate tablet formulation healthy male participant , fast condition , single dose 1000 mg .</brief_summary>
	<brief_title>A Comparative Study Bioavailability 3 New Abiraterone Acetate Tablets With Current Commercial Tablet</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , randomize ( study medication assign chance ) , single-center , 4-way crossover study ( method use switch participant one treatment arm another clinical trial ) single dose abiraterone acetate ( 1000 mg ) . The study consist 3 phase include screen phase ( 21 day ) , open-label treatment phase consist 4 single-dose treatment period , follow-up phase . All participant randomly assign 1 4 possible treatment sequence ensure receive follow treatment , one period . The 4 sequence follow : Sequence 1 : Treatment A , D , B , C ; Sequence 2 : Treatment B , A , C , D ; Sequence 3 : Treatment C , B , D , A ; Sequence 4 : Treatment D , C , A , B . After washout period 7 day , follow-up phase occur 5 7 day last study procedure . The duration participation study participant 47 day maximum 68 day ( include screen ) . Pharmacokinetics measure collection blood sample . Participants confine study center completion 96 hour pharmacokinetic assessment Day 5 treatment period . Safety evaluation adverse event , clinical laboratory test , electrocardiogram , vital sign , physical examination monitor throughout study .</detailed_description>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Have body weight less 50 kg Must nonsmoker , history smoking use nicotinecontaining substance within previous 2 month Must blood pressure 90 140 mmHg systolic , inclusive , high 90 mmHg diastolic Must 12lead electrocardiogram consistent normal cardiac conduction function Must agree use adequate contraception method deem appropriate investigator donate sperm study 3 month receive last dose study medication History current clinically significant medical illness include cardiac arrhythmia cardiac disease could interfere interpretation study result Clinically significant abnormal value hematology urinalysis ( screen ) Clinically significant abnormal physical examination vital sign 12lead electrocardiogram ( screen ) Usage prescription nonprescription medication , except acetaminophen , oral contraceptive hormonal replacement therapy within 14 day first dose study medication schedule Unable swallow solid , oral dosage form whole aid water ( participant may chew , divide , dissolve , crush study medication )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Healthy participant</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>Abiraterone</keyword>
</DOC>